Company: INKT
Filing Date: 2025-07-15
Form Type: 424B5
Source: 0001193125-25-159014
Chunk: 0

Company: MiNK Therapeutics, Inc.
Filing Date: 2025-07-15
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)
Registration No. 333-268143

PROSPECTUS SUPPLEMENT

(To Prospectus dated November 8, 2022)

Up to $50,000,000

Common Stock

This prospectus supplement
relates to the issuance and sale of up to $50,000,000 of our common stock, $0.00001 par value per share, from time to time through our sales agent, B. Riley Securities, Inc. (the “Sales Agent”). We have entered into an At Market Issuance
Sales Agreement (the “ATM Sales Agreement”) with the Sales Agent relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In accordance with the terms of the ATM Sales Agreement, we may
offer and sell shares up to $50,000,000 of our common stock from time to time through the Sales Agent.

We are subject to the offering limits in General
Instruction I.B.6 of Form S-3. As of July 14, 2025, the aggregate market value of our common stock held by non-affiliates, or public float, calculated for purposes
of General Instruction I.B.6 of Form S-3 is $64,907,955, which was calculated based on 1,011,500 shares of our outstanding common stock held by non-affiliates and a
price of $64.17 per share, the closing price of our common stock on July 11, 2025, which is the highest closing sale price of our common stock on the Nasdaq Capital Market within the prior 60 days. As of the date of this prospectus, we have not
sold any securities pursuant to General Instruction I.B.6 of Form S-3 during the 12 calendar months prior to, and including, the date of this prospectus. Pursuant to General Instruction I.B.6 of Form S-3, in no event will we sell securities in public primary offerings on Form S-3 with a value exceeding one-third of our public float
(as defined by General Instruction I.B.6) in any 12-calendar month period so long as our public float remains below $75.0 million.

As a result of the limitations on the maximum amount of shares that we are eligible to offer and sell under General Instruction I.B.6 of Form S-3, we may currently only offer and sell shares of our common stock having an aggregate offering